600789 Shandong Lukang Pharmaceutical
- 7.29
- -0.23-3.06%
Shandong Lukang Pharmaceutical News
Should You Buy Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) For Its Upcoming Dividend?
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) is abo
Shandong Lukang Pharmaceutical (600789.SH) plans to distribute 0.09 yuan per share in 2023. The ex-right and ex-dividend date is on June 20.
Shandong Lukang Pharmaceutical (600789.SH) announced the distribution plan for annual profits in 2023: distribute cash dividends per share...
China Approves Lukang Pharma's Anti-Asthma Injection
China's medical products administrator approved Shandong Lukang Pharmaceutical's (SHA:600789) doxofylline bronchodilator injection indicated for asthma, according to a Wednesday filing with the Shangh
Lukang Pharmaceutical (600789.SH): Doxofylline injection obtained drug registration certificate
Gelonghui, May 28, 丨 Lu Kang Pharmaceutical (600789.SH) announced that the company's holding subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (“SAITE”) has received a “Drug Registration Certificate” (approval number: 2024S00910) for doxofylline injections (referred to as “this drug”) issued by the State Drug Administration. Doxofylline is a novel derivative of methylxanthine. It is a bronchodilator that acts directly on the bronchi to relax bronchial smooth muscle. By inhibiting effects such as phosphodiesterase in smooth muscle cells, it relaxes smooth muscle, thereby suppressing asthma
We Think Shandong Lukang PharmaceuticalLtd (SHSE:600789) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) Looks Inexpensive But Perhaps Not Attractive Enough
With a price-to-earnings (or "P/E") ratio of 21.7x Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) may be sending bullish signals at the moment, given that almost half of all companies in China
Lukang Pharmaceutical (600789.SH): Net profit of 67.3076 million yuan in the first quarter, up 47.32% year on year
Gelonghui, April 23 | Lu Hang Pharmaceutical (600789.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 1,799 billion yuan, up 7.72% year on year; net profit attributable to shareholders of listed companies was 67.3076 million yuan, up 47.32% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 53.3717 million yuan, up 28.99% year on year; basic earnings per share were 0.08 yuan.
Shandong Lukang PharmaceuticalLtd's (SHSE:600789) Earnings Are Weaker Than They Seem
Last week's profit announcement from Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) was underwhelming for investors, despite headline numbers being robust. We did some digging and found some w
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Shandong Lukang PharmaceuticalLtd (SHSE:600789) has had a rough three months with its share price down 15%. It seems that the market might have completely ignored the positive aspects of the company
Lukang Pharmaceutical (600789.SH): Acarbose obtains approval notice for application for marketing of chemical raw materials
On February 2, Gelonghui Pharmaceutical (600789.SH) announced that it has received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for acarbose issued by the State Drug Administration, and the drug approved the marketing application. Acarbose is an α-glucosidase inhibitor that competes with oligosaccharides in the upper part of the small intestine and binds reversibly to α-glucosidase to inhibit the activity of various α-glucosidases such as maltase, isomaltase, glucoamylase, and sucrase, so that starch is broken down into sugars such as maltose (disaccharide), maltotriose and dextrin (oligosaccharides) at the rate at which glucose is broken down
Lukang Pharmaceutical (600789.SH): Levodopa obtained approval for marketing application as a chemical raw material
Zhitong Finance App News, Lu Kang Pharmaceutical (600789.SH) announced that the company received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for levodopa issued by the State Drug Administration, and the drug approved the marketing application. According to reports, levodopa is a dopamine-like anti-Parkinson's drug. It is a precursor substance for the synthesis of dopamine in the body. It has no pharmacological activity. It enters the center through the blood-brain barrier and is converted into dopamine through the action of dopa decarboxylase to exert pharmacological effects and improve the symptoms of Parkinson's disease. Since this drug can increase neurotransmitters such as dopamine and norepinephrine in the brain, it can also improve brain resistance to ammonia
Why Investors Shouldn't Be Surprised By Shandong Lukang Pharmaceutical Co.,Ltd.'s (SHSE:600789) Low P/E
Shandong Lukang Pharmaceutical Co.,Ltd.'s (SHSE:600789) price-to-earnings (or "P/E") ratio of 24.3x might make it look like a buy right now compared to the market in China, where around half of the co
Lu Kang Pharmaceutical (600789.SH): Yu Jing Health is no longer included in the scope of the company's merger
Lu Hong Pharmaceutical (600789.SH) announced that Beijing Yu Jing Health Technology Co., Ltd., a holding subsidiary of the company (“Yu Jing...
Does Shandong Lukang PharmaceuticalLtd (SHSE:600789) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to rui
Lukang Pharmaceutical (600789.SH): Azithromycin tablets produced by the subsidiary LuKangsaite can be used to treat mycoplasma infections
On December 11, Gelonghui Pharmaceutical (600789.SH) stated on the investor interactive platform that azithromycin tablets produced by LuKangsaite, a subsidiary of the company, can be used to treat mycoplasma infections.
Lukang Pharmaceutical (600789.SH): CIGB-814, an innovative drug for the treatment of rheumatoid arthritis, is currently in the pre-clinical research stage
On December 11, Gelonghui Pharmaceutical (600789.SH) stated on the investor interactive platform that CIGB-814, an innovative drug used by the company to treat rheumatoid arthritis, is currently still in the pre-clinical research stage, and the company is progressing steadily according to the R&D plan.
Shandong Lukang PharmaceuticalLtd's (SHSE:600789) Earnings Have Declined Over Three Years, Contributing to Shareholders 15% Loss
Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) shareholders should be happy to see the share price up 17% in the last quarter. But that doesn't help the fact that the three year return is le
Lukang Pharmaceutical's Piperacillin Sodium, Tazobactam Sodium Injection Passes Regulatory Evaluation
Shandong Lukang Pharmaceutical's (SHA:600789) piperacillin sodium and tazobactam sodium injection passed the generic drug quality and efficacy consistency evaluation of China's National Medical Produc
Analysis
Price Target
No Data
